Inhaled drug developer Pulmatrix has announced the appointment of Nocion Therapeutics CEO Rick Batycky to its board of directors. Batycky was a founder of Civitas Therapeutics, which developed Inbrija inhaled levodopa and which was acquired by Acorda in 2014. Prior to serving as Chief Scientific Officer at Civitas and then Chief Technology Officer at Acorda, Batycky had served as Chief Scientific Officer and Senior VP of R&D at Pulmatrix.
Pulmatrix CEO Ted Raad said, “Rick brings deep expertise in drug development to the board and we are thrilled to welcome him. His broad ranging experience in respiratory therapeutics, including Pulmatrix’s iSPERSE dry powder inhalation technology, will be invaluable as we consider opportunities to bring new therapeutics to market. We look forward to his strategic guidance as we strategically advance our iSPERSE platform.”
Batycky commented, “I believe that Pulmatrix’s iSPERSE platform technology has tremendous potential to improve the standard of care for patients suffering from serious pulmonary disease. I look forward to helping advance their critically important pipeline.”
Pulmatrix’s pipeline includes the Pulmazole (PUR1900) itraconazole DPI, which is in Phase 2 development for the treatment of allergic bronchopulmonary aspergillosis (ABPA). Earlier this year, Pulmatrix announced that it had partnered with Cip Tec on development of Pulmazole.
Read the Pulmatrix press release.
